Physicochemical stability of extemporaneously prepared clonidine solutions for use in neonatal abstinence syndrome.
chromatography
clonidine
neonatal abstinence syndrome
stability
Journal
Journal of clinical pharmacy and therapeutics
ISSN: 1365-2710
Titre abrégé: J Clin Pharm Ther
Pays: England
ID NLM: 8704308
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
01
07
2019
accepted:
04
07
2019
pubmed:
6
8
2019
medline:
19
3
2020
entrez:
6
8
2019
Statut:
ppublish
Résumé
Extemporaneously prepared clonidine admixture is increasingly used for the management of neonatal abstinence syndrome. However, its stability beyond 15 minutes at room temperature is currently unknown. Therefore, healthcare professionals must prepare clonidine admixtures multiple times a day while the treatment is indicated, resulting in subsequent limitations and problems. The aim of this study was to investigate the physicochemical stability of clonidine in commonly used pharmaceutical diluents at clinically relevant concentrations and temperatures. Glass bottles (n = 18) and plastic syringes (n = 18) containing 0.5 and 5 µg/mL of clonidine in either 5% glucose, 10% glucose or 0.9% normal saline were prepared and stored at 4°C for 7 days and at 35°C for 24 hours, respectively. Aliquots were withdrawn at predefined time points and analysed for the concentration of clonidine, changes in pH and colour, and particle content. No evidence of particle formation, or colour or pH change was observed throughout the study period. Clonidine retained more than 98% of its initial concentration when stored in the tested diluents at 4°C for 7 days and at 35°C for 24 hours. Our findings will allow healthcare professionals to prepare weekly dose of clonidine in glass bottles for storage in a refrigerator. The daily required dose of clonidine can be drawn aseptically from the glass bottle each day and stored in a plastic syringe at room temperature. Clonidine present in a plastic syringe can be administered via the nasogastric route 4-6 times a day. This practice would not only save nursing time and avoid delays in the timely administration of clonidine, but also reduce the risk of potential medication errors as well as preparation-associated costs.
Substances chimiques
Solutions
0
Clonidine
MN3L5RMN02
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
883-887Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-2331.
Doberczak TM, Kandal SR, Wilets I. Neonatal opiate abstinence syndrome in term and preterm infants. J Pediatr. 1991;118(6):933-937.
Lam SK, To WK, Duthie SJ, Ma HK. Narcotic addiction in pregnancy with adverse maternal and perinatal outcome. Aust N Z J Obstet Gynaecol. 1992;32(3):216-221.
Leikin JB, Mackendrick WP, Maloney GE, et al. Use of clonidine in the prevention and management of neonatal abstinence syndrome. Clin Toxicol. 2009;47(6):551-555.
Agthe AG, Kim GR, Mathias KB, et al. Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. Pediatrics. 2009;123(5):e849-e856.
Hünseler C, Balling G, Röhlig C, et al. Continuous infusion of clonidine in ventilated newborns and infants: a randomized controlled trial. Pediatr Crit Care Med. 2014;15(6):511-522.
Arenas-López S, Riphagen S, Tibby SM, et al. Use of oral clonidine for sedation in ventilated paediatric intensive care patients. Intensive Care Med. 2004;30(8):1625-1629.
Gray A, Wright J, Goodey V, et al. Injectable Drugs Guide. London, UK: Pharmaceutical Press; 2011.
Sinko PJ. Martin's Physical Pharmacy and Pharmaceutical Sciences. 7th ed. New York, NY: Wolters Kluwer; 2016.
Harmanjeet H, Zaidi S, Ming LC, Wanandy T, Patel RP. Physicochemical stability of voriconazole in elastomeric devices. Eur J Hosp Pharm. 2018;25:e88-e92.
U.S. Pharmacopeia-National Formulary (USP 39 NF 34). General Requirements Injection. Rockville, MD: United States Pharmacopeial Convention; 2016.
Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012;307(18):1934-1940.
Uebel H, Wright IM, Burns L, et al. Epidemiological evidence for a decreasing incidence of neonatal abstinence syndrome, 2000-11. Paediatr Perinat Epidemiol. 2016;30(3):267-273.
Kocherlakota P. Neonatal abstinence syndrome. Pediatrics. 2014;134(2):e547-e561.
Liu A, Bjorkman T, Stewart C, Nanan R. Pharmacological treatment of neonatal opiate withdrawal: between the devil and the deep blue sea. Int J Pediatr. 2011;2011:935631.
de Graaf J, van Lingen RA, Simons S, et al. Long-term effects of routine morphine infusion in mechanically ventilated neonates on children's functioning: five-year follow-up of a randomized controlled trial. Pain. 2011;152(6):1391-1397.
Surran B, Visintainer P, Chamberlain S, Kopcza K, Shah B, Singh R. Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. J Perinatol. 2013;33(12):954-959.
Hunt DG, Chandler C, Ulrich DA, et al. USP Controlled Room Temperature Range Expansion. http://www.thermosafe.com/blog/wp-content/uploads/2014/02/S20102.pdf. Accessed July 1, 2019.
Nawawi NM, Sapian AR, Majid N, et al. Hospital Designs in Tropical Malaysia-towards a Green Agenda. The UIA/PHG Annual Healthcare Forum. Toronto, Canada: IIDEX Canada; 2013. http://irep.iium.edu.my/37628/17/FINAL_-Tropical_Hospital_Design_for_Malaysia-_240314.pdf. Accessed July 1, 2019.